TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06558097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)
Study: NCT00586339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Control
Description: Intramuscular injection, 3 doses
Study: NCT01972152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen(TM) 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen(TM) 1 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-Pen(TM) 1 mg
Study: NCT03575013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a antineoplastic agent belonging to the taxoid family
Study: NCT04184050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4002
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4002
Description: IV infusion
Study: NCT03729609

Intervention type: DRUG
Intervention: Brentuximab vedotin (Genetical Recombination)
Description: Brentuximab vedotin Intravenous Infusion
Study: NCT04626518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
Study: NCT06558097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single SC dose of matching placebo (administered by single or multiple injections)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single SC dose of matching placebo (administered by single or multiple injections)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single SC dose of matching placebo (administered by single or multiple injections)
Study: NCT04626518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
Study: NCT03413800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide-Dexamethasone-DLI
Description: Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
Study: NCT04023487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient, Empowered, Active Living-Telehealth (REAL-T)
Description: REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
Study: NCT04626518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: Administered via IV infusion at a dose of 800 mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Administered via oral tablet at a dose of 120 mg QD
Study: NCT01809769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells low-dose group
Description: Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells mid-dose group
Description: Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells high-dose group
Description: Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
Study: NCT01220687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNO
Description: Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
Study: NCT01533987

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice Plus
Description: Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Juice Plus
Description: Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
Study: NCT00601731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197
Description: Blood test, 40-months and 60-months children

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Blood test, 40-months and 60-months children
Study: NCT03563001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide(160ug) and Formoterol(4.5ug) bid
Description: For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide(160ug) and Formoterol(4.5ug) bid
Description: For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
Study: NCT03578055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDD with UDCA
Description: Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
Study: NCT04388631

Intervention type: OTHER
Intervention: Coronavirus Disease 2019
Description: male patients who have developed COVID-19
Study: NCT01437189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
Study: NCT02735460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Andago V2.0
Description: The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
Study: NCT04626518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Administered via oral tablet at a dose of 120 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a dose of 20 mg QD
Study: NCT04103346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air filtration with air purifier with hepa filter
Description: long-term (4 week) air filtration with the Holmes HAP8650B-NU-1 air purifier in the residence of low-income seniors impacted by roadway pollutants.
Study: NCT04626518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a dose of 20 mg QD
Study: NCT04103346

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: air purifier running with air filter removed
Study: NCT04169009

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Intradermal injection of Zostavax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Intradermal injection of Zostavax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Intradermal injection of Zostavax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Intradermal injection of Zostavax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Given to subjects in Arm 4 who've never had a herpes zoster vaccine
Study: NCT04511494

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peanut (bamba)
Description: OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
Study: NCT04419519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy
Description: Venetoclax monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax with anti CD20 monoclonal antibody
Description: Venetoclax with anti CD20 monoclonal antibody
Study: NCT04626518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Administered via IV infusion at a dose of 400 mg/25 mg Q6W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: Administered via IV infusion at a dose of 800 mg/200 mg Q3W
Study: NCT03677427

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation in breast cancer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation in breast cancer
Study: NCT02124161

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13-valent pneumococcal conjugate vaccine
Description: One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal Inactivated Influenza Vaccine
Description: One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal Inactivated Influenza Vaccine
Description: One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13-valent pneumococcal conjugate vaccine
Description: One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
Study: NCT04014946

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implantation
Description: implantation of the Lumax 540 single/dual chamber ICD or successor
Study: NCT03872154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist-guided shared decision-making
Description: Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility.
Study: NCT00778544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension
Study: NCT03598608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion every 3 weeks (Q3W)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion every 3 weeks (Q3W)
Study: NCT01149694

Intervention type: DRUG
Group type: OTHER
Intervention: PUR 0110 Rectal Enema or Placebo Enema
Description: 187.5 mg/60 g

Intervention type: DRUG
Group type: OTHER
Intervention: PUR 0110 Rectal Enema or Placebo Enema
Description: 375 mg/60 g

Intervention type: DRUG
Group type: OTHER
Intervention: PUR 0110 Rectal Enema or Placebo Enema
Description: 750 mg/60 g

Intervention type: DRUG
Group type: OTHER
Intervention: PUR 0110 Rectal Enema or Placebo Enema
Description: 1500 mg/60 g
Study: NCT03058874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra-vascular lung water measurements by ultrasound
Description: Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
Study: NCT03058874

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard protocol of fluid management in hemodialysis
Description: The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
Study: NCT05429411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silicone gel
Description: At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach \>21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
Study: NCT02992730

Intervention type: BEHAVIORAL
Intervention: No Intervention
Description: No Intervention
Study: NCT03090165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: 400mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: 600mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg PO
Study: NCT04474873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: we administer 15 cc of 0.5% bupivacaine between the erector spine muscle and the transverse process. The distribution of bupivacain was observed on ultrasound.
Study: NCT01277185

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Calcium Diet
Description: The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Calcium Diet
Description: The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
Study: NCT02096354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: To be dosed after RRx-001 or regorafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: To be dosed after RRx-001 or regorafenib
Study: NCT04593745

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular pressure measurment
Description: Intraocular pressure measurmentt using iCare devise: TONOPEN
Study: NCT03162627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
Study: NCT04402216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life-led preparation
Description: Support from a certified child life specialist in preparation for MRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life-led preparation
Description: Support from a certified child life specialist in preparation for MRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MRI preparation video
Description: A descriptive video about what to expect when undergoing MRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KindVR Virtual Reality MRI Preparation Experience
Description: A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
Study: NCT03375437

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood and tumor samples
Description: FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2\*10mL EDTA)
Study: NCT03900650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High provocation manipulation
Description: Participants will engage in a laboratory task and will then report their emotions following the task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High provocation manipulation
Description: Participants will engage in a laboratory task and will then report their emotions following the task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low provocation manipulation
Description: Participants will engage in a laboratory task and will then report their emotions following the task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low provocation manipulation
Description: Participants will engage in a laboratory task and will then report their emotions following the task.
Study: NCT03598608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion every 3 weeks (Q3W)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion every 3 weeks (Q3W)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion every 3 weeks (Q3W)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: Administered as an IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: Administered as an IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: Administered as an IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: Administered as an IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: Administered as an IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: Administered as an IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: Administered as an IV infusion Q3W